Literature DB >> 15336297

Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram.

S J Wilson1, J E Bailey, A S Rich, M Adrover, J Potokar, D J Nutt.   

Abstract

BACKGROUND: SSRIs suppress rapid eye movement (REM) sleep, probably by increasing serotonin in the brainstem, and also increase sleep fragmentation. Although in the UK, paroxetine (PAR) and citalopram (CIT) have recommended doses of 20 mg/day for the treatment of depression, the recommended dose of CIT in USA is higher (40 mg). If similar doses of PAR and CIT have similar effects on central serotonin then they should have similar effects on sleep measures in volunteers.
METHOD: This was a randomised, double blind placebo controlled crossover study in 12 healthy volunteers. Subjects took PAR 20 mg mane, CIT 20 mg mane or placebo mane for 3 days and sleep was recorded overnight at home on the third night. Standard measures of sleep were derived.
RESULTS: REM sleep was significantly suppressed and sleep fragmentation increased by both drugs. Measures of REM sleep and sleep continuity previously found to be altered by SSRIs were considered together and compared with placebo as a 'serotonin response'; this was significantly greater in the PAR group.
CONCLUSIONS: Sleep effects typical of SSRIs were greater with PAR 20 mg/day than CIT 20 mg/day, suggesting greater effects on 5HT uptake blockade.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15336297     DOI: 10.1016/j.euroneuro.2003.11.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  10 in total

1.  Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment.

Authors:  Szilvia Vas; Zita Kátai; Diána Kostyalik; Dorottya Pap; Eszter Molnár; Péter Petschner; Lajos Kalmár; György Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2012-06-24       Impact factor: 3.575

2.  The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose.

Authors:  E M McGlashan; L S Nandam; P Vidafar; D R Mansfield; S M W Rajaratnam; S W Cain
Journal:  Psychopharmacology (Berl)       Date:  2018-09-15       Impact factor: 4.530

3.  Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls.

Authors:  Robin L Carhart-Harris; David J Nutt; Marcus R Munafo; David M Christmas; Sue J Wilson
Journal:  Psychopharmacology (Berl)       Date:  2009-07-08       Impact factor: 4.530

4.  Chronic escitalopram treatment caused dissociative adaptation in serotonin (5-HT) 2C receptor antagonist-induced effects in REM sleep, wake and theta wave activity.

Authors:  Diána Kostyalik; Zita Kátai; Szilvia Vas; Dorottya Pap; Péter Petschner; Eszter Molnár; István Gyertyán; Lajos Kalmár; László Tóthfalusi; Gyorgy Bagdy
Journal:  Exp Brain Res       Date:  2014-01-07       Impact factor: 1.972

Review 5.  Antidepressants and sleep: a qualitative review of the literature.

Authors:  Sue Wilson; Spilios Argyropoulos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Sleep Disturbances in Traumatic Brain Injury: A Meta-Analysis.

Authors:  Natalie Grima; Jennie Ponsford; Shantha M Rajaratnam; Darren Mansfield; Matthew P Pase
Journal:  J Clin Sleep Med       Date:  2016-03       Impact factor: 4.062

7.  A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase.

Authors:  David M Christmas; Jp Potokar; Simon Jc Davies
Journal:  Neuropsychiatr Dis Treat       Date:  2011-07-13       Impact factor: 2.570

8.  Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.

Authors:  Steven C Leiser; Deborah Iglesias-Bregna; Ligia Westrich; Alan L Pehrson; Connie Sanchez
Journal:  J Psychopharmacol       Date:  2015-07-14       Impact factor: 4.153

9.  A randomized phase 1 single-dose polysomnography study of ASP8062, a GABAB receptor positive allosteric modulator.

Authors:  Mark Walzer; Ruishan Wu; Maha Ahmad; Jon Freeman; Gary Zammit; Gerard J Marek
Journal:  Psychopharmacology (Berl)       Date:  2021-01-12       Impact factor: 4.530

10.  Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men.

Authors:  Sue Wilson; Astrid-Maria Højer; Jeppe Buchberg; Johan Areberg; David J Nutt
Journal:  J Psychopharmacol       Date:  2015-08-07       Impact factor: 4.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.